Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

IITRI’s New Zika Model Supports Countermeasure Development

by Global Biodefense Staff
May 10, 2016
Zika Virus Diagnostics and Countermeasure Development

Zika Virus Diagnostics and Countermeasure DevelopmentIIT Research Institute (IITRI) scientists have developed a novel mouse model for Zika infections using the current viral strain responsible for outbreaks in Central and South America, and more than 1000 locally-acquired and imported cases in the U.S. and territories.

The Zika mouse model is urgently needed to rapidly test new drugs and vaccines against the same strain associated with microcephaly in newborns.

IITRI is one of the first labs in the country to have acquired the PRV ABC59 strain, an isolate of Zika virus from the current outbreak.

Robert Baker, PhD, Manager of the Microbiology and Molecular Biology Division at IITRI, emphasized the importance of using the current strain to evaluate new treatments against the Zika virus. “Most labs are working with old isolates—as old as 1947 in fact.  As you know, viruses and other organisms change over time, and those older isolates have never been associated with microcephaly. We are at the cutting edge of the effort to get an effective treatment or prevention out to the world.”

“We’re very excited to be able to offer a more relevant Zika mouse infection model to study the viral disease pathogenesis and find new treatments against the current Zika threat,” said David McCormick, PhD, DABT, Director of IITRI. “We have been working hard to have the model available for research to catch up with the emerging outbreak.”

IITRI has a long history of providing preclinical efficacy, safety, and toxicology services to the pharmaceutical, biotechnology, biodefense, consumer products and chemical industries as well as the U.S. Government. IITRI offers a wide range of services to support preclinical drug development of small molecules, vaccines, and biologics.

Tags: Animal ModelsEmerging ThreatsZika

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
Poxvirus Proteins Enable Early Strike on Immune Defences
Pathogens

Poxvirus Proteins Enable Early Strike on Immune Defences

July 15, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC